ID: ALA4071886

Max Phase: Preclinical

Molecular Formula: C20H18N4O2S

Molecular Weight: 378.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(c1cccc(S(C)(=O)=O)c1)c1ccc2[nH]nc(-c3ccncc3)c2c1

Standard InChI:  InChI=1S/C20H18N4O2S/c1-24(15-4-3-5-17(12-15)27(2,25)26)16-6-7-19-18(13-16)20(23-22-19)14-8-10-21-11-9-14/h3-13H,1-2H3,(H,22,23)

Standard InChI Key:  IFTCODKQCZXXCX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 378.46

Molecular Weight (Monoisotopic): 378.1150

AlogP: 3.80

#Rotatable Bonds: 4

Polar Surface Area: 78.95

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 3.95

CX LogP: 2.62

CX LogD: 2.62

Aromatic Rings: 4

Heavy Atoms: 27

QED Weighted: 0.58

Np Likeness Score: -1.52

References

1. Scott JD, DeMong DE, Greshock TJ, Basu K, Dai X, Harris J, Hruza A, Li SW, Lin SI, Liu H, Macala MK, Hu Z, Mei H, Zhang H, Walsh P, Poirier M, Shi ZC, Xiao L, Agnihotri G, Baptista MA, Columbus J, Fell MJ, Hyde LA, Kuvelkar R, Lin Y, Mirescu C, Morrow JA, Yin Z, Zhang X, Zhou X, Chang RK, Embrey MW, Sanders JM, Tiscia HE, Drolet RE, Kern JT, Sur SM, Renger JJ, Bilodeau MT, Kennedy ME, Parker EM, Stamford AW, Nargund R, McCauley JA, Miller MW..  (2017)  Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.,  60  (7): [PMID:28245354] [10.1021/acs.jmedchem.7b00045]

Source

Source(1):

• Scientific Literature